share_log

Arcutis Biotherapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144

Arcutis Biotherapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144

Arcutis Biotherapeutics | 144:擬議出售證券
美股SEC公告 ·  08/03 04:28

牛牛AI助理已提取核心訊息

Arcutis Biotherapeutics, Inc. officer Todd Franklin Watanabe is set to sell 14,487 shares of the company's common stock on August 2, 2024. The shares to be sold were acquired on August 1, 2024, through a restricted stock vest from Arcutis Biotherapeutics. The transaction is part of Watanabe's compensation and does not involve any additional payment. This sale comes without any reported transactions in the past three months for Watanabe.
Arcutis Biotherapeutics, Inc. officer Todd Franklin Watanabe is set to sell 14,487 shares of the company's common stock on August 2, 2024. The shares to be sold were acquired on August 1, 2024, through a restricted stock vest from Arcutis Biotherapeutics. The transaction is part of Watanabe's compensation and does not involve any additional payment. This sale comes without any reported transactions in the past three months for Watanabe.
Arcutis Biotherapeutics公司官員託德·富蘭克林·渡邊計劃在2024年8月2日出售14,487股公司普通股。這些股票是通過來自Arcutis Biotherapeutics的限制性股票授予計劃於2024年8月1日獲得的。該交易是渡邊的補償計劃的一部分,不涉及任何額外的支付。渡邊此次出售,並未舉報過去三個月的任何交易。
Arcutis Biotherapeutics公司官員託德·富蘭克林·渡邊計劃在2024年8月2日出售14,487股公司普通股。這些股票是通過來自Arcutis Biotherapeutics的限制性股票授予計劃於2024年8月1日獲得的。該交易是渡邊的補償計劃的一部分,不涉及任何額外的支付。渡邊此次出售,並未舉報過去三個月的任何交易。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。